Incidence of Grade 3–4 Laboratory Abnormalities Measured from 177Lu-PSMA Start to 90 Days After Last Dose
| Abnormality | Patients (n) | Incidence (n) |
|---|---|---|
| Hemoglobin | 49 | 17 (35%) |
| Platelet count | 47 | 6 (13%)* |
| Neutrophils | 49 | 1 (2%) |
| Aspartate aminotransferase | 49 | 2 (4%) |
↵* Four of 6 had low platelets at baseline, with further reductions at follow-up (1 had chemotherapy before 177Lu-PSMA); 1 of 6 had normal platelets at baseline, with reductions seen after chemotherapy and at follow-up; 1 of 6 had normal platelets at baseline, with reduction at follow-up.